Abstract
Background
The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen are used for the treatment of osteoporosis and cancer, respectively, in women. The impairment of both the Atrial Natriuretic Peptide (ANP) cell signaling system and the translocation of nuclear factor-kappa B (NF-kB) to the cell nucleus are associated with detrimental cardiovascular effects and inflammation. The effects of SERMs on these parameters in the cardiac tissue of estrogen-deficient rats has not been reported.
Methods
We investigated the effects of raloxifene and tamoxifen on ANP signaling, p65 NF-kB nuclear translocation, cardiac histology and contractility. Female rats were divided into five groups: control (SHAM), ovariectomized (OVX), OVX-treated 17-β-estradiol (E), OVX-treated raloxifene (RLX) and OVX-treated tamoxifen (TAM). The treatments started 21 days after ovariectomy and continued for 14 days.
Results
Ovariectomy reduced ANP mRNA in the left atrium (LA), decreased the content of ANP protein in the LA and in plasma, and increased the level of p65 NF-kB nuclear translocation in the left ventricle. Both 17-β-estradiol and SERMs were able to reverse these alterations, which were induced by the estrogen deficient state. The hemodynamic and cardiac structural parameters analyzed in the present work were not modified by the interventions.
Conclusions
Our study demonstrates, for the first time, the additional benefits of raloxifene and tamoxifen in an estrogen-deficient state. These include the normalization of plasmatic and cardiac ANP levels and cardiac p65 NF-kB translocation. Therefore, these treatments promote cardiovascular protection and may contribute to the prevention of cardiac dysfunction observed long-term in postmenopausal women.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, Goetze JP. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol 2014;11 (7):403–12.
Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J. Med 1998;339(5):321–8.
Vesely DL, de Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 2009;57(1):29–32.
Gu J, D’Andrea M, Seethapathy M, McDonnell C, Cichon R. Physical overdistension converts ventricular cardiomyocytes to acquire endocrine property and regulate ventricular atrial natriuretic peptide production. Angiology 1991;42(3):173–86.
Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Lond) 2001;101(5):447–53.
Kuroski de Bold ML. Estrogen, natriuretic peptides and the renin-angiotensin system. Cardiovasc Res 1999;41(3):524–31.
Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction: potential mechanisms and early predictors. Circulation 1993;87(3):755–63.
Li X, Stark GR. NFkappaB-dependent signaling pathways. Exp Hematol 2002;30(4):285–96.
Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kB in the heart: to be or not to NF-kB. Circ Res 2011; 108(9): 1122–32.
Kumar R, Yong QC, Thomas CM. Do multiple nuclear factor kappa B activation mechanisms explain its varied effects in the heart? Ochsner J 2013; 13(1):157–65.
García-Becerra R, Santos N, Díaz L, Camacho J. Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 2013;14(1):108–45.
Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013;8(2):135–55.
Christodoulakos GE, Lambrinoudaki IV, Botsis DC. The cardiovascular effects of selective estrogen receptor modulators. Ann N Y Acad Sci 2006;1092:374–84.
Lamas AZ, Caliman IF, Dalpiaz PLM, de Melo AF, Abreu GR, Lemos EM, et al. Comparative effects of estrogen, raloxifene and tamoxifen on endothelial dysfunction, inflammatory markers and oxidative stress in ovariectomized rats. Life Sci 2015;124:101–9.
Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat 2012;132(3):1107–18.
Messalli EM, Scaffa C. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health 2010;1:11–20.
Vellaichamy E, Khurana ML, Fink J, Pandey KN. Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A. J Biol Chem 2005;280 (19):19230–42.
Maier HJ, Schips TG, Wietelmann A, Krüger M, Brunner C, Sauter M, et al. Cardiomyocyte-specific IκB kinase (IKK)/NF-kB activation induces reversible inflammatory cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2012;109(29):11794–9.
Kiemer AK, Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 2001;60(Suppl. 3):iii68–70.
Vollmar AM. The role of atrial natriuretic peptide in the immune system. Peptides 2005;26(6):1086–94.
Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, et al. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology 2007;148(1):332–6.
Mitkiewicz M, Kuropatwa M, Kurowska E, Gorczyca W. Different effects of soluble and particulate guanylyl cyclases on expression of inflammatory cytokines in rat peripheral blood mononuclear cells. Immunobiology 2011;216 (3):423–30.
Mezzasoma L, Antognelli C, Talesa VN. Atrial natriuretic peptide down-regulates LPS/ATP-mediated IL-1β release by inhibiting NF-kB, NLRP3 inflammasome and caspase-1 activation in THP-1 cells. Immunol Res 2016;64 (1):303–12.
De Medeiros ARS, Lamas AZ, Caliman IF, Dalpiaz PLM, Firmes LB, de Abreu GR, et al. Tibolone has anti-in flammatory effects in estrogen-deficient female rats on the natriuretic peptide system and TNF-alpha. Regul Pept 2012;179(1–3):55–60.
Spinetti A, Margutti A, Bertolini S, Bernardi F, BiFulco G, degli Uberti EC, et al. Hormonal replacement therapy affects calcitonin gene-related peptide and atrial natriuretic peptide secretion in postmenopausal women. Eur J Endocrinol 1997;137(6):664–9.
Sato M, Rippy MK, Bryant HU. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J 1996;10(8):905–12.
Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339(22):1609–18.
Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer 2010;10:313.
Dalpiaz PLM, Lamas a Z, Caliman IF, Medeiros a RS, Abreu GR, Moysés MR, et al. The chronic blockade of angiotensin I-converting enzyme eliminates the sex differences of serum cytokine levels of spontaneously hypertensive rats. Braz J Med Biol Res 2013;46(2):171–7.
Wang X, Ren B, Liu S, Sentex E, Tappia PS, Dhalla NS. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol 2003;94(2):752–63.
Gutkowska J, Genest J, Thibault G, Garcia R, Larochelle P, Cusson JR, et al. Circulating forms and radioimmunoassay of atrial natriuretic factor. Endocrinol Metab Clin North Am 1987;16(1):183–98.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–54.
Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162(1):156–9.
Davel APC, Fukuda LE, De Sá LL, Munhoz CD, Scavone C, Sanz-Rosa D, et al. Effects of isoproterenol treatment for 7 days on inflammatory mediators in the rat aorta. Am J Physiol Heart Circ Physiol 2008;295(1):H211–9.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193(1):265–75.
Tanno AP, das Neves VJ, Rosa KT, Cunha TS, Giordano FCL, Calil CM, et al. Nandrolone and resistance training induce heart remodeling: role of fetal genes and implications for cardiac pathophysiology. Life Sci 2011;89(17–18):631–7.
Bissoli NS, Medeiros ARS, Santos MCS, Busato VCW, Jarske RD, Abreu GR, et al. Long-term treatment with supraphysiological doses of nandrolone decanoate reduces the sensitivity of Bezold-Jarisch reflex control of heart rate and blood pressure. Pharmacol Res 2009;59(6):379–84.
Belo NO, Silva-Barra J, Carnio EC, Antunes-Rodrigues J, Gutkowska J, Dos Reis AM. Involvement of atrial natriuretic peptide in blood pressure reduction induced by estradiol in spontaneously hypertensive rats. Regul Pept 2004; 117 (1):53–60.
Clericoa Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31(9):487–98.
Bupha-Intr T, Wattanapermpool J. Regulatory role of ovarian sex hormones in calcium uptake activity of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 2006;291(3):H1101–8.
Chu SH, Goldspink P, Kowalski J, Beck J, Schwertz DW. Effect of estrogen on calcium-handling proteins, beta-adrenergic receptors, and function in rat heart. Life Sci 2006;79(13):1257–67.
Ribeiro RF, Pavan BMM, Potratz FF, Fiorim J, Simoes MR, Dias FMV, et al. Myocardial contractile dysfunction induced by ovariectomy requires AT1 receptor activation in female rats. Cell Physiol Biochem 2012;30(1):1–12.
Paigel AS, Ribeiro RF, Fernandes AA, Targueta GP, Vassallo DV, Stefanon I. Myocardial contractility is preserved early but reduced late after ovariectomy in young female rats. Reprod Biol Endocrinol 2011;9(1):54.
Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323 (4):236–41.
Testa M, Yeh M, Lee P, Fanelli R, Loperfido F, Berman JW, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28(4):964–71.
Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ. Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 2005;146(2):728–35.
Ghisletti S, Meda C, Maggi A, Vegeto E. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 2005;25(8):2957–68.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27(5):1201–6.
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93(4):704–11.
Frasor J, El-Shennawy L, Stender JD, Kastrati I. NF-kB affects estrogen receptor expression and activity in breast cancer through multiple mechanisms. Mol Cell Endocrinol 2015;418(Pt 3):235–9.
Jankowski M, Rachelska G, Donghao W, McCann SM, Gutkowska J. Estrogen receptors activate atrial natriuretic peptide in the rat heart. Proc Natl Acad Sci U S A 2001;98(20):11765–70.
Jamdade VS, Mundhe NA, Kumar P, Tadla V, Lahkar M. Raloxifene inhibits NF-kB pathway and potentiates anti-tumour activity of cisplatin with simultaneous reduction in its nephrotoxictiy. Pathol Oncol Res 2016;22(1):145–53.
Dutertre M, Smith CL. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J Pharmacol Exp Ther 2000;295(2):431–7.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lamas, A.Z., Nascimento, A.M., Medeiros, A.R.S. et al. The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen improve ANP levels and decrease nuclear translocation of NF-kB in estrogen-deficient rats. Pharmacol. Rep 69, 798–805 (2017). https://doi.org/10.1016/j.pharep.2017.03.004
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.pharep.2017.03.004